{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:01:55Z","timestamp":1791151315373,"version":"4.1.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.critrevonc.2010.07.007","type":"journal-article","created":{"date-parts":[[2010,8,11]],"date-time":"2010-08-11T09:12:40Z","timestamp":1281517960000},"page":"321-329","source":"Crossref","is-referenced-by-count":64,"title":["Peripheral T-cell lymphoma \u2013 Not otherwise specified"],"prefix":"10.1016","volume":"79","author":[{"given":"Kerry J.","family":"Savage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s J.M.","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano A.","family":"Pileri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2010.07.007_bib0005","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0010","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0015","first-page":"300","article-title":"Lymphoid malignancies in Nebraska: a hypothesis","volume":"70","author":"Weisenburger","year":"1985","journal-title":"Nebr Med J"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0020","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/00001648-199009000-00004","article-title":"A case-control study of non-Hodgkin's lymphoma and the herbicide 2,4- dichlorophenoxyacetic acid (2,4-D) in eastern Nebraska","volume":"1","author":"Zahm","year":"1990","journal-title":"Epidemiology"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0025","first-page":"899","article-title":"Soft tissue sarcoma and non-Hodgkin's lymphoma in relation to phenoxyherbicide and chlorinated phenol exposure in western Washington","volume":"78","author":"Woods","year":"1987","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0030","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/bjc.1989.290","article-title":"Occupation and lymphoid neoplasms","volume":"60","author":"La Vecchia","year":"1989","journal-title":"Br J Cancer"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0035","first-page":"5503s","article-title":"Non-Hodgkin's lymphoma and occupational exposure","volume":"52","author":"Scherr","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0040","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ajim.4700180310","article-title":"Environmental epidemiology of non-Hodgkin's lymphoma in eastern Nebraska","volume":"18","author":"Weisenburger","year":"1990","journal-title":"Am J Ind Med"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0045","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s00428-004-1077-2","article-title":"Nodal peripheral T-cell lymphomas and, in particular, their lymphoepithelioid (Lennert's) variant are often derived from CD8(+) cytotoxic T-cells","volume":"445","author":"Geissinger","year":"2004","journal-title":"Virchows Arch"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0050","series-title":"Malignant lymphomas: other than Hodgkin's disease: histology, cytology, ultrastructure, immunology","author":"Lennert","year":"1978"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0055","first-page":"1372","article-title":"Cutaneous T-cell lymphomas (including rare subtypes). Current concepts II","volume":"89","author":"Paulli","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0740-2570(03)00013-3","article-title":"Splenic involvement by peripheral T-cell and NK-cell neoplasms","volume":"20","author":"Chan","year":"2003","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0065","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","article-title":"Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score","volume":"24","author":"Went","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0070","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3324\/haematol.10767","article-title":"Expression of CD52 in peripheral T-cell lymphoma","volume":"92","author":"Piccaluga","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0075","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1080\/10428190902926981","article-title":"CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies","volume":"50","author":"Geissinger","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0080","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2141.2009.07606.x","article-title":"Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy","volume":"145","author":"Jiang","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0085","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/PAS.0b013e31802d68e9","article-title":"Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression","volume":"31","author":"Attygalle","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0090","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/01.pas.0000209855.28282.ce","article-title":"Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma","volume":"30","author":"Dorfman","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0095","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/modpathol.3800625","article-title":"Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified","volume":"19","author":"Grogg","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0100","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/10428199409051685","article-title":"Combined immunophenotyping and karyotyping in peripheral T cell lymphomas demonstrating different clonal and nonclonal chromosome aberrations in T helper cells","volume":"15","author":"Schlegelberger","year":"1994","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0105","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/ajh.2830350205","article-title":"Cytogenetic findings in 21 cases of peripheral T-cell lymphoma","volume":"35","author":"Inwards","year":"1990","journal-title":"Am J Hematol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0110","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/gcc.20386","article-title":"Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: a matrix-based CGH approach","volume":"46","author":"Thorns","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0115","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0002-9440(10)63742-X","article-title":"Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations","volume":"164","author":"Zettl","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0120","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1172\/JCI26833","article-title":"Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets","volume":"117","author":"Piccaluga","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0125","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","article-title":"The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells","volume":"109","author":"de Leval","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0130","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1200\/JCO.2006.09.4474","article-title":"Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas","volume":"25","author":"Cuadros","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0135","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2006-04-017632","article-title":"Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) study","volume":"108","author":"Dupuis","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0140","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1023\/A:1008439620513","article-title":"Report of the European task force on lymphomas: workshop on peripheral T-cell lymphomas","volume":"9","author":"Campo","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0145","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1182\/blood.V75.2.434.434","article-title":"Peripheral T-cell lymphoma associated with hemophagocytic syndrome","volume":"75","author":"Falini","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0150","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0155","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/annonc\/mdm265","article-title":"FDG-PET in T-cell and NK-cell neoplasms","volume":"18","author":"Kako","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0160","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00277-008-0494-8","article-title":"Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies","volume":"87","author":"Khong","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0165","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2002-09-2778","article-title":"Utility of FDG-PET scanning in lymphoma by WHO classification","volume":"101","author":"Elstrom","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0170","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0175","first-page":"1860","article-title":"Report of the committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0180","first-page":"112:3","article-title":"Prognosis and primary therapy of PTCLs","author":"Savage","year":"2008","journal-title":"ASH Annu Meeting Abstr"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0185","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte (GELA)","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0190","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0195","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1182\/blood.V89.12.4514","article-title":"Evaluation of the revised European\u2013American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma","volume":"89","author":"Melnyk","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0200","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1023\/A:1008418727472","article-title":"Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the REAL classification","volume":"9","author":"Lopez-Guillermo","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0205","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/cncr.20531","article-title":"Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi","volume":"101","author":"Morabito","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0210","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/1042819021000030054","article-title":"Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification","volume":"44","author":"Arrowsmith","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0215","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0959-8049(01)00344-6","article-title":"Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the revised European\u2013American lymphoma (REAL) classification","volume":"38","author":"Kim","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0220","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-04-0371","article-title":"CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified","volume":"10","author":"Ishida","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0225","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood-2002-05-1352","article-title":"Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL","volume":"103","author":"Tsuchiya","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0230","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1097\/01.pas.0000173238.17331.6b","article-title":"Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified","volume":"29","author":"Asano","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0235","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2006.09.4490","article-title":"Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications \u2013 a study from the Lunenburg Lymphoma Biomarker Consortium","volume":"25","author":"de","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0240","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/sj.leu.2403960","article-title":"Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas","volume":"19","author":"Martinez-Delgado","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0245","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0250","series-title":"Presentation at the 10th International Conference on Malignant Lymphoma","article-title":"T-cell lymphomas in studies of the German high-grade NHL study group (DSHNHL)","author":"Schmitz","year":"2008"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0255","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1182\/blood.V108.11.2464.2464","article-title":"The VIP-ABVD regimen is not superior to the CHOP 21 for the treatment of non epidermotropic peripheral T cell lymphoma. Final results of the \u201cLTP95\u201d protocol of the GOELAMS","volume":"108","author":"Gressin","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0260","first-page":"2010","article-title":"Does high-dose therapy and autologous hematopoietic stem cell transplantation have a role in the primary treatment of peripheral T-cell lymphomas? ASH evidence-based review 2008","volume":"39\u201341","author":"Shustov","year":"2008","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0265","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/sj.thj.6200359","article-title":"Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study","volume":"5","author":"Reimer","year":"2004","journal-title":"Hematol J"},{"issue":"11.","key":"10.1016\/j.critrevonc.2010.07.007_bib0270","article-title":"Autologous stem cell transplantation as first line therapy in peripheral T cell lymphomas update of a prospective multicenter study","volume":"104","author":"Reimer","year":"2004","journal-title":"ASH Annu Meeting Abstr"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0275","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","article-title":"Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from the Gel-Tamo study group","volume":"79","author":"Rodriguez","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0280","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0285","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"Mercadal","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0290","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.critrevonc.2010.07.007_bib0295","first-page":"437","volume":"94","author":"D\u2019Amore","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0300","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2002.02.125","article-title":"Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma","volume":"20","author":"Gisselbrecht","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0305","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1200\/JCO.2004.12.032","article-title":"Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"22","author":"Mounier","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0310","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1080\/10428190412331272749","article-title":"Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant","volume":"45","author":"Jagasia","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0315","first-page":"1372","article-title":"High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience","volume":"88","author":"Rodriguez","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0320","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1046\/j.1365-2141.2003.04203.x","article-title":"Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype","volume":"120","author":"Song","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0325","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.bmt.1702867","article-title":"High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas","volume":"27","author":"Blystad","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0330","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0335","first-page":"S10","article-title":"Anthracycline resistance: the problem and its current definition","volume":"24","author":"Gianni","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0340","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1023\/A:1008409601731","article-title":"Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients","volume":"9","author":"Zinzani","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0345","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","article-title":"Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience","volume":"92","author":"Arkenau","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0350","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0355","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","article-title":"Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study","volume":"60","author":"Kim","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0360","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1158\/1078-0432.CCR-06-1275","article-title":"Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)","volume":"12","author":"Rodig","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2010.07.007_bib0365","series-title":"American Society of Hematology 2008 Annual Meeting","article-title":"PROPEL: a multi-center phase 2 open-label study of pralatrexate (PDX) with vitamin B12 and folic acid supplementation in patients with replapsed or refractory peripheral T-cell lymphoma","author":"O\u2019Connor","year":"2008"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842810001745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842810001745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T07:14:44Z","timestamp":1591773284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842810001745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S1040842810001745"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2010.07.007","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}